<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phgenomics</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакогенетика и фармакогеномика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacogenetics and Pharmacogenomics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0527</issn><issn pub-type="epub">2686-8849</issn><publisher><publisher-name>LLC "Izdatelstvo OKI"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24411/2588-0527-2019-10050</article-id><article-id custom-type="elpub" pub-id-type="custom">phgenomics-125</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОГЕНЕТИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOGENETICS STUDY</subject></subj-group></article-categories><title-group><article-title>Особенности комплексного фармакогенетического подхода к терапии розувастатином у пациентов с ИБС</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кононов</surname><given-names>С. И.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полоников</surname><given-names>А. В.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маль</surname><given-names>Г. С.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФГБОУ ВО «Курский государственный медицинский университет» Минздрава России</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2019</year></pub-date><volume>0</volume><issue>2</issue><fpage>19</fpage><lpage>20</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кононов С.И., Полоников А.В., Маль Г.С., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Кононов С.И., Полоников А.В., Маль Г.С.</copyright-holder><copyright-holder xml:lang="en">Кононов С.И., Полоников А.В., Маль Г.С.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/125">https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/125</self-uri><abstract><p>Проведён комплексный фармакогенетический анализ эффективности гиполипидемической терапии розувастатином у больных ИБС, стабильной стенокардией напряжения II–III функциональных классов в зависимости от носительства полиморфных вариантов генов, регулирующих липидный обмен и генов мембранных транспортёров.</p><p> </p></abstract><kwd-group xml:lang="ru"><kwd>фармакогенетическое исследование</kwd><kwd>розувастатин</kwd><kwd>ишемическая болезнь сердца</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Alfonsi JE, Hegele RA, Gryn SE. Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? Curr Atheroscler Rep. 2016;18(5):24.</mixed-citation><mixed-citation xml:lang="en">Alfonsi JE, Hegele RA, Gryn SE. Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? Curr Atheroscler Rep. 2016;18(5):24.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344–1353.</mixed-citation><mixed-citation xml:lang="en">Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344–1353.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Granér M, Varpula M, Kahri J, et al. Association of carotid intima-media thickness with angiographic severity and extent of coronary artery disease. Am J Cardiol. 2006;97(5):624–629.</mixed-citation><mixed-citation xml:lang="en">Granér M, Varpula M, Kahri J, et al. Association of carotid intima-media thickness with angiographic severity and extent of coronary artery disease. Am J Cardiol. 2006;97(5):624–629.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
